Hongri Pharmaceutical: Injectable Polymyxin E, Methanesulfonate Sodium Obtains Approval for Clinical Trials

Hongri Pharmaceutical Announcement: The company recently received the drug clinical trial approval notice issued by the National Medical Products Administration. After review, the company’s application for the injectable polymyxin E sulfate sodium meets the relevant requirements for drug registration, and approval is granted to conduct clinical trials of this product. This drug is suitable for acute or chronic infections caused by Gram-negative bacteria sensitive strains, especially infections caused by Pseudomonas aeruginosa sensitive strains.

View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin